Cytokinetics to Announce First Quarter Results on April 27, 2017
April 13 2017 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is
scheduled to report first quarter results on Thursday, April 27,
2017 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics’ senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and
the company’s outlook for the future.
The conference call will be simultaneously
webcast and can be accessed from the homepage and in the Investors
& Media section of Cytokinetics’ website at
www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 46685336.
An archived replay of the webcast will be
available via Cytokinetics' website until May 4, 2017. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 46685336 from April 27, 2017 at 5:30 PM
Eastern Time until May 4, 2017.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal troponin activator
(FSTA). Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by
the European Medicines Agency. Cytokinetics is
preparing for the potential commercialization
of tirasemtiv in North
America and Europe and has granted an option to
Astellas for development and commercialization in other
countries. Cytokinetics is collaborating with Astellas to
develop CK-2127107, a next-generation fast skeletal muscle
activator. CK-2127107 is the subject of two ongoing Phase 2
clinical trials enrolling patients with spinal muscular atrophy and
chronic obstructive pulmonary disease. Cytokinetics is
collaborating with Amgen Inc. to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other countries. Astellas holds an
exclusive worldwide license to develop and commercialize
CK-2127107. Licenses held by Amgen and Astellas are
subject to Cytokinetics' specified co-development and
co-commercialization rights. For additional information
about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act’s safe harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the
properties and potential benefits of Cytokinetics’ drug candidates
and potential drug candidates. Such statements are based on
management’s current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024